Switch to:
More From Other Websites
Is a Surprise Coming for Sarepta Therapeutics (SRPT) This Earnings Season? Feb 27 2017
How the state’s newest Duchenne biotechs are getting a boost from patient groups Feb 27 2017
5 Stocks Set for Explosive Breakouts Feb 24 2017
[2/23] This Week’s Earnings Revisions Movers Feb 23 2017
The Contrary Indicators Are Piling Up Feb 22 2017
Bull Market Ahead for the Biotech Industry in 2017? Today's Reports on Sarepta Therapeutics and... Feb 22 2017
Did Gilead's new tool for speeding drug approval come at bargain-basement price? Feb 21 2017
Sarepta Sells Priority Review Voucher for $125M Feb 21 2017
Sarepta Leads Biotech Movers on Voucher Deal News Feb 21 2017
Sarepta sells FDA review voucher for $125M, but analyst questions price Feb 21 2017
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Feb 21 2017
Sarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M Feb 21 2017
Santhera opens Mass. office as local Duchenne ecosystem grows Feb 17 2017
Oppenheimer Stays Bullish On Sarepta As Concerns Continue To Swirl Feb 16 2017
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results and Recent... Feb 15 2017
Defending Sarepta Against Blowback From the Marathon Pharma Steroid Price Gouging Scandal Feb 14 2017
Marathon Pharma will pause launch of Duchenne muscular dystrophy drug after outcry over $89,000... Feb 13 2017
Sarepta Muscular Dystrophy Drug Faces Competition Feb 10 2017
FDA approves Marathon Pharma's Duchenne muscular dystrophy drug Feb 09 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK